<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38747018</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>15</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>Presence of SARS-CoV-2 RNA in COVID-19 survivors with post-COVID symptoms 2 years after hospitalization: The VIPER study.</ArticleTitle><Pagination><StartPage>e29676</StartPage><MedlinePgn>e29676</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.29676</ELocationID><Abstract><AbstractText>The SARS-CoV-2 VIrus PERsistence (VIPER) study investigated the presence of long-lasting SARS-CoV-2 RNA in plasma, stool, urine, and nasopharyngeal samples in COVID-19 survivors. The presence of SARS-CoV-2 RNA reverse transcription polymerase chain reactions (RT-PCR) were analyzed within plasma, stool, urine, and nasopharyngeal swab samples in COVID-19 survivors with post-COVID symptoms and a comparison group of COVID-19 survivors without post-COVID symptoms matched by age, sex, body mass index and vaccination status. Participants self-reported the presence of any post-COVID symptom (defined as a symptom that started no later than 3 months after the initial infection). Fifty-seven (57.9% women, age: 51.1, standard deviation [SD]: 10.4 years) previously hospitalized COVID-19 survivors with post-COVID symptoms and 55 (56.4% women, age: 50.0, SD: 12.8 years) matched individuals who had a past SARS-CoV-2 infection without post-COVID symptoms were evaluated 27 (SD 7.5) and 26 (SD 8.7) months after hospital discharge, respectively. The presence of SARS-CoV-2 RNA was identified in three nasopharyngeal samples of patients with post-COVID symptoms (5.2%) but not in plasma, stool, or urine samples. Thus, SARS-CoV-2 RNA was not identified in any sample of survivors without post-COVID symptoms. The most prevalent post-COVID symptoms consisted of fatigue (93%), dyspnea, and pain (both, 87.7%). This study did not find SARS-CoV-2 RNA in plasma, stool, or urine samples, 2&#xa0;years after the infection. A prevalence of 5.2% of SARS-CoV-2 RNA in nasopharyngeal samples, suggesting a potential active or recent reinfection, was found in patients with post-COVID symptoms. These results do not support the association between SARS-CoV-2 RNA in plasma, stool, urine, or nasopharyngeal swab samples and post-COVID symptomatology in the recruited population.</AbstractText><CopyrightInformation>&#xa9; 2024 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-de-Las-Pe&#xf1;as</LastName><ForeName>C&#xe9;sar</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation, Universidad Rey Juan Carlos (URJC), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neuroplasticity and Pain (CNAP), SMI, Department of Health Science and Technology, Faculty of Medicine, Aalborg University, Aalborg, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torres-Macho</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hospital Universitario Infanta Leonor-Virgen de la Torre, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruiz-Ruig&#xf3;mez</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hospital Universitario Doce de Octubre, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arrieta-Ortubay</LastName><ForeName>Estibaliz</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hospital Universitario Doce de Octubre, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez-Rebollo</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hospital Universitario Infanta Leonor-Virgen de la Torre, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akasbi-Moltalvo</LastName><ForeName>M&#xed;riam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hospital Universitario Infanta Leonor-Virgen de la Torre, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pardo-Guimer&#xe1;</LastName><ForeName>Virginia</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hospital Universitario Infanta Leonor-Virgen de la Torre, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan-Murua</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hospital Universitario Infanta Leonor-Virgen de la Torre, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER de Enfermedades Infecciosas (CIBERINFEC), ISCIIII, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lumbreras-Bermejo</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hospital Universitario Doce de Octubre, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pellicer-Valero</LastName><ForeName>Oscar J</ForeName><Initials>OJ</Initials><AffiliationInfo><Affiliation>Image Processing Laboratory (IPL), Universitat de Val&#xe8;ncia, Parc Cient&#xed;fic, Paterna,&#xa0;Val&#xe8;ncia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giordano</LastName><ForeName>Rocco</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Center for Neuroplasticity and Pain (CNAP), SMI, Department of Health Science and Technology, Faculty of Medicine, Aalborg University, Aalborg, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oral and Maxillofacial Surgery, Aalborg University Hospital, Aalborg, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arendt-Nielsen</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Center for Neuroplasticity and Pain (CNAP), SMI, Department of Health Science and Technology, Faculty of Medicine, Aalborg University, Aalborg, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gastroenterology &amp; Hepatology, Mech-Sense, Clinical Institute, Aalborg University Hospital, Aalborg, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Steno Diabetes Center North Denmark, Clinical Institute, Aalborg University Hospital, Aalborg, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franco-Moreno</LastName><ForeName>Anabel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hospital Universitario Infanta Leonor-Virgen de la Torre, Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Consejer&#xed;a de Sanidad, Comunidad de Madrid</Agency><Country/></Grant><Grant><Agency>Novo Nordisk Fonden</Agency><Country/></Grant><Grant><GrantID>DNRF121</GrantID><Agency>Danish National Research Foundation</Agency><Country/></Grant><Grant><GrantID>NNF21OC0067235</GrantID><Agency>Novo Nordisk Foundation</Agency><Country/></Grant><Grant><Agency>Fondo Europeo De Desarrollo Regional-Recursos REACT-UE del Programa Operativo de Madrid 2014-2020</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="Y">RNA, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017741" MajorTopicYN="Y">Survivors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009305" MajorTopicYN="Y">Nasopharynx</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="Y">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005243" MajorTopicYN="Y">Feces</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">RNA</Keyword><Keyword MajorTopicYN="N">long&#x2010;COVID</Keyword><Keyword MajorTopicYN="N">plasma</Keyword><Keyword MajorTopicYN="N">post&#x2010;COVID&#x2010;19</Keyword><Keyword MajorTopicYN="N">stool</Keyword><Keyword MajorTopicYN="N">urine</Keyword><Keyword MajorTopicYN="N">viral persistence</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>15</Day><Hour>4</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38747018</ArticleId><ArticleId IdType="doi">10.1002/jmv.29676</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>World Health Organization. WHO Coronavirus (COVID&#x2010;19) Dashboard. Accessed April 5, 2024.&#xa0;http://covid19.who.int/</Citation></Reference><Reference><Citation>Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real&#x2010;world effectiveness of COVID&#x2010;19 vaccines: a literature review and meta&#x2010;analysis. Int J Infect Dis. 2022;114:252&#x2010;260.</Citation></Reference><Reference><Citation>Fern&#xe1;ndez&#x2010;de&#x2010;las&#x2010;Pe&#xf1;as C. Long COVID: current definition. Infection. 2022;50:285&#x2010;286.</Citation></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV, WHO Clinical Case Definition Working Group on Post&#x2010;COVID&#x2010;19 Condition. A clinical case definition of post&#x2010;COVID&#x2010;19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22:e102&#x2010;e107.</Citation></Reference><Reference><Citation>Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post&#x2010;coronavirus disease 2019 (COVID&#x2010;19) condition or long COVID: a meta&#x2010;analysis and systematic review. J Infect Dis. 2022;226:1593&#x2010;1607.</Citation></Reference><Reference><Citation>Han Q, Zheng B, Daines L, Sheikh A. Long&#x2010;term sequelae of COVID&#x2010;19: a systematic review and meta&#x2010;analysis of one&#x2010;year follow&#x2010;up studies on post&#x2010;COVID symptoms. Pathogens. 2022;11:269.</Citation></Reference><Reference><Citation>Fernandez&#x2010;De&#x2010;Las&#x2010;Pe&#xf1;as C, Notarte KI, Macasaet R, et al. Persistence of post&#x2010;COVID symptoms in the general population two years after SARS&#x2010;CoV&#x2010;2 infection: a systematic review and meta&#x2010;analysis. J Infect. 2024;88:77&#x2010;88.</Citation></Reference><Reference><Citation>Rahmati M, Udeh R, Yon DK, et al. A systematic review and meta&#x2010;analysis of long&#x2010;term sequelae of COVID&#x2010;19 2&#x2010;year after SARS&#x2010;CoV&#x2010;2 infection: a call to action for neurological, physical, and psychological sciences. J Med Virol. 2023;95:e28852.</Citation></Reference><Reference><Citation>Amdal CD, Pe M, Falk RS, et al. Health&#x2010;related quality of life issues, including symptoms, in patients with active COVID&#x2010;19 or post COVID&#x2010;19; a systematic literature review. Qual Life Res. 2021;30:3367&#x2010;3381.</Citation></Reference><Reference><Citation>Tene L, Bergroth T, Eisenberg A, David SSB, Chodick G. Risk factors, health outcomes, healthcare services utilization, and direct medical costs of patients with long COVID. Int J Infect Dis. 2023;128:3&#x2010;10.</Citation></Reference><Reference><Citation>Hayes LD, Ingram J, Sculthorpe NF. More than 100 persistent symptoms of SARS&#x2010;CoV&#x2010;2 (Long COVID): a scoping review. Front Med. 2021;8:750378.</Citation></Reference><Reference><Citation>Fern&#xe1;ndez&#x2010;de&#x2010;las&#x2010;Pe&#xf1;as C, Raveendran AV, Giordano R, Arendt&#x2010;Nielsen L. Long COVID or post&#x2010;COVID&#x2010;19 condition: past, present and future research directions. Microorganisms. 2023;11:2959.</Citation></Reference><Reference><Citation>Chen B, Julg B, Mohandas S, Bradfute SB. RECOVER Mechanistic Pathways Task Force. Viral persistence, reactivation, and mechanisms of long COVID. eLife. 2023;12:e86015.</Citation></Reference><Reference><Citation>Proal AD, VanElzakker MB, Aleman S, et al. SARS&#x2010;CoV&#x2010;2 reservoir in post&#x2010;acute sequelae of COVID&#x2010;19 (PASC). Nat&#xa0;Immunol. 2023;24:1616&#x2010;1627.</Citation></Reference><Reference><Citation>Fern&#xe1;ndez&#x2010;de&#x2010;las&#x2010;Pe&#xf1;as C, Torres&#x2010;Macho J, Macasaet R, et al. Presence of SARS&#x2010;CoV&#x2010;2 RNA in COVID&#x2010;19 survivors with post&#x2010;COVID symptoms: a systematic review of the literature. Clin&#xa0;Chem&#xa0;Lab&#xa0;Med. 2024;62:1044&#x2010;1052. doi:10.1515/cclm-2024-0036</Citation></Reference><Reference><Citation>Hedman E, Lj&#xf3;tsson B, Blom K, et al. Telephone versus internet administration of self&#x2010;report measures of social anxiety, depressive symptoms, and insomnia: psychometric evaluation of a method to reduce the impact of missing data. J Med Internet Res. 2013;15:e229.</Citation></Reference><Reference><Citation>Herrmann&#x2010;Lingen C, Buss U, Snaith RP Hospital Anxiety and Depression Scale&#x2014;Deutsche Version (HADS&#x2010;D). Verlag Hans Huber; 2011.</Citation></Reference><Reference><Citation>Fern&#xe1;ndez&#x2010;de&#x2010;las&#x2010;Pe&#xf1;as C, Rodr&#xed;guez&#x2010;Jim&#xe9;nez J, Palacios&#x2010;Ce&#xf1;a M, et al. Psychometric properties of the Hospital Anxiety and Depression Scale (HADS) in previously hospitalized COVID&#x2010;19 patients. Int J Environ Res Public Health. 2022;19:9273.</Citation></Reference><Reference><Citation>Olss&#xf8;n I, Mykletun A, Dahl AA. The hospital anxiety and depression rating scale: a cross&#x2010;sectional study of psychometrics and case finding abilities in general practice. BMC Psychiatry. 2005;5:46.</Citation></Reference><Reference><Citation>Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28:193&#x2010;213.</Citation></Reference><Reference><Citation>Fern&#xe1;ndez&#x2010;de&#x2010;las&#x2010;Pe&#xf1;as C, Palacios&#x2010;Ce&#xf1;a M, Rodr&#xed;guez&#x2010;Jim&#xe9;nez J, et al. Psychometric properties of the functional impairment checklist (FIC) as a disease&#x2010;specific patient&#x2010;reported outcome measure (PROM) in previously hospitalized COVID&#x2010;19 survivors with long&#x2010;COVID. Int J Environ Res Public Health. 2022;19:11460.</Citation></Reference><Reference><Citation>Zhang X, Lu S, Li H, et al. Viral and antibody kinetics of COVID&#x2010;19 patients with different disease severities in acute and convalescent phases: a 6&#x2010;month follow&#x2010;up study. Virol&#xa0;Sin. 2020;35:820&#x2010;829.</Citation></Reference><Reference><Citation>Natarajan A, Zlitni S, Brooks EF, et al. Gastrointestinal symptoms and fecal shedding of SARS&#x2010;CoV&#x2010;2 RNA suggest prolonged gastrointestinal infection. Med. 2022;3:371&#x2010;387.</Citation></Reference><Reference><Citation>Tejerina F, Catalan P, Rodriguez&#x2010;Grande C, et al. Post&#x2010;COVID&#x2010;19 syndrome. SARS&#x2010;CoV&#x2010;2 RNA detection in plasma, stool, and urine in patients with persistent symptoms after COVID&#x2010;19. BMC Infect Dis. 2022;22:211.</Citation></Reference><Reference><Citation>Craddock V, Mahajan A, Spikes L, et al. Persistent circulation of soluble and extracellular vesicle&#x2010;linked spike protein in individuals with post&#x2010;acute sequelae of COVID&#x2010;19. J Med Virol. 2023;95:e28568.</Citation></Reference><Reference><Citation>Bussani R, Zentilin L, Correa R, et al. Persistent SARS&#x2010;CoV&#x2010;2 infection in patients seemingly recovered from COVID&#x2010;19. J Pathol. 2023;259:254&#x2010;263.</Citation></Reference><Reference><Citation>Zollner A, Koch R, Jukic A, et al. Post&#x2010;acute COVID&#x2010;19 is characterized by gut viral antigen persistence in inflammatory bowel diseases. Gastroenterology. 2022;163:495&#x2010;506.</Citation></Reference><Reference><Citation>Stein SR, Ramelli SC, Grazioli A, et al. SARS&#x2010;CoV&#x2010;2 infection and persistence in the human body and brain at autopsy. Nature. 2022;612:758&#x2010;763.</Citation></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, et al. Multiple early factors anticipate post&#x2010;acute COVID&#x2010;19 sequelae. Cell. 2022;185:881&#x2010;895.</Citation></Reference><Reference><Citation>Kuodi P, Gorelik Y, Gausi B, Bernstine T, Edelstein M. Characterization of post&#x2010;COVID syndromes by symptom cluster and time period up to 12 months post&#x2010;infection: a systematic review and meta&#x2010;analysis. Int J Infect Dis. 2023;134:1&#x2010;7.</Citation></Reference><Reference><Citation>Swank Z, Senussi Y, Manickas&#x2010;Hill Z, et al. Persistent circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post&#x2010;acute coronavirus disease 2019 sequelae. Clin Infect Dis. 2023;76:e487&#x2010;e490.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>